# Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

> clinical trial · VERIFIED · 2026-08-06

Status: ACTIVE_NOT_RECRUITING · Sponsor: AstraZeneca · Condition: Non-Small-Cell Lung Carcinoma NSCLC

- Company: AstraZeneca
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT02453282

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.